Nonhuman primate models of Parkinson's disease (Q34665820)

3 August 2017

1 reference

title

Nonhuman primate models of Parkinson's disease (English)

1 reference

3 August 2017

1 reference

0 references

1

Marina E Emborg

1 reference

3 August 2017

publication date

1 January 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

48

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

339-355

1 reference

Nocturnal sleep structure and temperature slope in MPTP treated monkeys.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Functional MRI studies in awake rhesus monkeys: methodological and analytical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Aged monkeys exhibit behavioral deficits indicative of widespread cerebral dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The proteasomal inhibition model of Parkinson's disease: "Boon or bust"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Proteasome inhibition and Parkinson's disease modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Howard Henry Tooth (1856-1925)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys--and in Lewy body-containing human brain specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Recommendations for prevention and therapy of person's exposed to B virus (Cercopithecine herpesvirus 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP binds to neuromelanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Noninvasive assessment of aromatic L-amino acid decarboxylase activity in aging rhesus monkey brain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Primate models of movement disorders of basal ganglia origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Evaluation of animal models of Parkinson's disease for neuroprotective strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Long-term MPTP-treated monkeys are resistant to GM1 systemic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Rest tremor in rhesus monkeys with MPTP-induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Basal ganglia lesions after MPTP administration in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Genetics of Parkinson's disease and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Correlation of R2 with total iron concentration in the brains of rhesus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Mapping dopamine function in primates using pharmacologic magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Actions of 6-hydroxydopamine quinones on catecholamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Preoperative indicators of clinical outcome following stereotaxic pallidotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The etiology of Parkinson's disease with emphasis on the MPTP story

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Dissociated functional recovery in parkinsonian monkeys following transplantation of astroglial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Premorbid exercising in specific cognitive tasks prevents impairment of performance in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The etiopathogenesis of Parkinson disease and suggestions for future research. Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Model fusion, the next phase in developing animal models for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Lack of nigrostriatal pathology in a rat model of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The role of alpha-synuclein in Parkinson's disease: insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Loss of D2 receptor binding with age in rhesus monkeys: importance of correction for differences in striatal size

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Parkinson's disease management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The role of radiotracer imaging in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Cellular replacement therapy for Parkinson's disease--where we are today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Cell transplantation for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Point source concentration of GDNF may explain failure of phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Molecular markers of early Parkinson's disease based on gene expression in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Crossroads in GDNF therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

The effect of aging on pars compacta of the substantia nigra in rhesus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Neural repair strategies for Parkinson's disease: insights from primate models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

α-Synuclein in Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Cancer prevention: a new era beyond cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Parkinson disease in twins: an etiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

6-hydroxy-dopamine induced degeneration of central monoamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ILAR.48.4.339

21 January 2018

Identifiers

DOI

10.1093/ILAR.48.4.339

1 reference

3 August 2017

1 reference